A double-blind study comparing idazoxan and bupropion in bipolar depressed patients

Journal of Affective Disorders

Volumn 56, Issue 2-3, 1999, Pages 237-243

  Grossman, Fred ^a   Potter, William Z ^a   Brown, Elizabeth A ^b   Maislin, Greg ^c  

^a ELI LILLY AND COMPANY   (United States)

^b 30 South 15th Street   (United States)

^c Biomedical Statistical Consulting   (United States)

Author keywords

Biologic effects; Bipolar; Bipolar depressed; Bupropion; Depression; Idazoxan

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; IDAZOXAN; LITHIUM; PLACEBO;

ADULT; ARTICLE; BIPOLAR DEPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEIZURE; VOMITING;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; BUPROPION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IDAZOXAN; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0033369377     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00041-5     Document Type: Article

References (20)

1. Azorin J.M., Pupeschi G., Valli M., Joanny P., Raucoules D., Lancon C., Tissot R. Plasma3-methoxy-4-hydroxyphenylglycol in manic patients: relationships with clinical variables. Acta Psychiatr. Scand. 81:1990;14-18.
2. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
3. Feldman H.A. Families of lines, random effects in linear regression analysis. J. Appl. Physiol. 64:(4):1988;1721-1732.
4. Garcia-Sevilla J.A., Gurman J., Garcia-Vallejo P., Fuster M.J. Biochemical and functional evidence of supersensitive platelet alpha-2 adrenoreceptors in major affective disorder: effect of long-term lithium carbonate treatment. Arch. Gen. Psychiatry. 43:1986;51-57.
5. Gerner R.H., Fairbanks L., Anderson G.M., Young J.G., Scheinin M., Linnoila M., Hare T.A., Shaywitz B.A., Cohen D.J. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am. J. Psychiatry. 141:1984;1533-1540.
6. Gibbons R.D., Hedeker D., Waternaux C., Davis J.M. Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol. Bull. 24:(3):1988;438-443.
7. Glue P., Wilson S., Lawson C., Campling G.M., Franklin M., Cowen P.J., Nutt D.J. Acute and chronic idazoxan in normal volunteers: biochemical, physiological, and psychological effects. J. Psychopharmacol. 5:(4):1991;394-401.
8. Goodwin F.K., Jamison K.R. Goodwin F.K., Jamison K.R. Biochemical and Pharmacologic Studies in Manic-Depressive Illness. 1990;Oxford University Press, New York.
9. Keith R.A., Howe B.B., Salama A.I. Modulation of peripheral beta-1 and alpha-2 receptor sensitivities by the administration of the tricyclic antidepressant, imipramine, alone and in combination with alpha-2 antagonists to rats. J. Pharmacol. Exp. Ther. 236:1985;356-363.
10. Koslow S.H., Maas J.W., Bowden C., Davis J.M., Hanin I., Javoid J. Cerebrospinal fluid and urinary biogenic amines and metabolites in depression, mania, and healthy controls. Arch. Gen. Psychiatry. 40:1983;999-1010.
11. Lavori P.W. Clinical trials in psychiatry: should protocol deviation censor patient data. Neurolpsychopharmacology. 6:1992;39-48.
12. Manji H.K., Chen G., Bitran J.A., Gusovsky F., Potter W.Z. Idazoxan down-regulates beta adrenergic receptors on C6 glioma cells in vitro. Eur. J. Pharmacol. 3:1992;275-282.
13. Manji H.K., Potter W.Z. Monoaminergic systems. Young L.T., Joffe R.T. Bipolar Disorder, Biological Models and Their Clinical Applications. 1:1997;1-40 Marcel Dekker, New York.
14. Osman O.T., Rudorfer M.V., Potter W.Z. Idazoxan: a selective alpha-2 antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch. Gen. Psychiatry. 46:1989;958-959.
15. Pinder R.M., Sitsen J.M.A. Alpha-2-adrenoceptor antagonists as antidepressants: the search for selectivity. Dahl S., Gram L., Paul S., Potter W.Z. Clinical Pharmacology in Psychiatry. 1987;Springer-Verlag, Berlin.
16. Potter W.Z. Bipolar depression: specific treatments. J. Clin. Psychiatry. 59:(Suppl. 18):1998;30-36.
17. Potter W.Z., Grossman F., Dawkins K., Manji H.K. Initial clinical psychopharmacological studies of alpha-2 adrenoceptor antagonists in volunteers and depressed patients. Montgomery S.A., Corn T.H. Psychopharmacology of Depression, British Association For Psychopharmacology Monograph No. 13. 1994;Oxford University Press, New York.
18. Potter W.Z., Grossman F., Rudorfer M.V. Noradrenergic function and depressive disorders. Mann J.J., Kupfer D.J. The Biology of Depressive Disorders: A Systems Perspective. 1993;Plenum Press, New York.
19. Swann A. Is bipolar depression a specific biological entity. Young L.T., Joffe R.T. Bipolar Disorder: Biological Models and Their Clinical Applications. 10:1997;255-285 Marcel Dekker, New York.
20. Wilson S.J., Glue P., Nutt D.J. The effects of the alpha-2 adrenoceptor antagonist idazoxan on sleep in normal volunteers. J. Psychopharmacology. 5:(2):1991;105-110.